Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
  1. 4 Option exercise Director acquired 9,470 shares (option exercise)
  2. 4 Open-market sale Director sold 15,470 shares at an average $328.54 ($5,082,480)
  3. 144 Insider Sale of Securities
  4. 144/A Insider Sale of Securities
  5. 4 Planned sale SVP and CFO sold 258 shares at $323.04 ($83,344)
  6. 4 Grant or award Director acquired 894 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 144 Insider Sale of Securities
  9. 8-K Event Executive or director change · Regulation FD disclosure
  10. 4 Grant or award President and CEO acquired 13,066 shares (grant or award)
  11. 4 Grant or award SVP and CFO acquired 3,784 shares (grant or award)
  12. 4 Open-market sale Senior VP, Chief Pharma Dev. sold 14,113 shares at an average $341.32 ($4,817,104)
  13. 4 Grant or award Pres., R&D, and CMO acquired 4,382 shares (grant or award)
  14. 4 Grant or award General Counsel acquired 3,187 shares (grant or award)
  15. 4 Grant or award Chief Commercial Officer acquired 3,386 shares (grant or award)
  16. 4 Planned sale General Counsel sold 415 shares at $335.00 ($139,025)
  17. 4 Planned sale SVP and CFO sold 1,961 shares at an average $324.96 ($637,248)
  18. 4 Planned sale Chief Commercial Officer sold 1,834 shares at an average $325.98 ($597,840)
  19. 144 Insider Sale of Securities
  20. 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,227 shares at an average $341.07 ($418,488)

Page 9 of 62 · 1,224 filings